SORA

Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

Homovanillic acid in CSF of mild stage Parkinson's disease patients correlates with motor impairment.

Stefani, A; Pierantozzi, M; Olivola, E; Galati, S; Cerroni, R; D'Angelo, V; Hainsworth, AH; Saviozzi, V; Fedele, E; Liguori, C (2017) Homovanillic acid in CSF of mild stage Parkinson's disease patients correlates with motor impairment. Neurochem Int, 105. pp. 58-63. ISSN 1872-9754 https://doi.org/10.1016/j.neuint.2017.01.007
SGUL Authors: Hainsworth, Atticus Henry

[img]
Preview
PDF Accepted Version
Available under License Creative Commons Attribution Non-commercial.

Download (1MB) | Preview

Abstract

In Parkinson's disease (PD), several efforts have been spent in order to find biochemical parameters able to identify the progression of the pathological processes at the basis of the disease. It is already known that advanced PD patients manifesting dyskinesia are featured by the high homovanillic acid (HVA)/dopamine (DA) ratio, suggesting the increased turnover of DA in these patients. Less clear is whether similar changes affect mild and moderate stages of the disease (between 1 and 2.5 of Hoehn & Yahr -H&Y- stage). Hence, here we tested whether cerebrospinal fluid (CSF) concentrations of DA and its major metabolites, either 3,4-dihydroxyphenylacetic acid (DOPAC) or HVA, correlate with motor performance in mild and moderate PD patients. CSF samples were collected after 2 days of anti-PD drugs washout, via lumbar puncture (LP) performed 130 min following administration of oral levodopa (LD) dose (200 mg). LP timing was determined in light of our previous tests clarifying that 2 h after oral LD administration CSF DA concentration reaches a plateau, which was un-respective of PD stage or duration. DA, DOPAC and HVA were assayed by high performance liquid chromatography in a group of 19 patients, distributed in two groups on the basis of the H&Y stage with a cut-off of 1.5. In these PD patients, HVA was correlated with DOPAC (R = 0,56, p < 0,01) and both HVA and DOPAC CSF levels increased in parallel with the motor impairment. More importantly, HVA correlated with motor impairment measured by the Unified Parkinson's Disease Score -III (UPDRS) (R = 0.61; p < 0.0001). The present findings showed the early alteration of the DA pre-synaptic machinery, as documented by the progressive increase of CSF HVA concentrations, which also correlated with PD motor impairment. Therefore, we suggest the potential use of measuring the CSF HVA level as a possible biomarker of PD stage changes in order to monitor the effectiveness of PD-modifying pharmacological therapies.

Item Type: Article
Additional Information: © 2017. This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/
Keywords: CSF, Dopamine, HVA, Mild Parkinson's disease, Motor impairment, 1101 Medical Biochemistry And Metabolomics, 1109 Neurosciences
SGUL Research Institute / Research Centre: Academic Structure > Molecular and Clinical Sciences Research Institute (MCS)
Journal or Publication Title: Neurochem Int
ISSN: 1872-9754
Language: eng
Dates:
DateEvent
May 2017Published
18 January 2017Published Online
16 January 2017Accepted
Publisher License: Creative Commons: Attribution-Noncommercial-No Derivative Works 4.0
PubMed ID: 28108196
Go to PubMed abstract
URI: https://openaccess.sgul.ac.uk/id/eprint/108551
Publisher's version: https://doi.org/10.1016/j.neuint.2017.01.007

Actions (login required)

Edit Item Edit Item